Similar Posts
Ultragenyx CEO talks the company’s path to profitability in developing drugs for rare diseases
ShareShare Article via FacebookShare Article via TwitterShare Article via LinkedInShare Article via Email Dr. Emil Kakkis, Ultragenyx founder & CEO, joins ‘Closing Bell Overtime’ to talk drug trials and development, its path to profitability and more.
Cramer’s Mad Dash: Chewy
CNBC’s Jim Cramer delivers his daily Mad Dash.
Final Call: BAC, AAPL and more
The final call of the day with the ‘Options Action’ traders.
Customs union has not helped UK firms, economist says
Gerard Lyons tells CNBC there is too much fear about leaving the EU without a deal.
Watch CNBC’s full interview with Charles Schwab’s Liz Ann Sonders, Veritas’ Greg Branch and Virtus’ Joe Terranova
ShareShare Article via FacebookShare Article via TwitterShare Article via LinkedInShare Article via Email Liz Ann Sonders, Charles Schwab chief investment strategist, Greg Branch, Veritas Financial Group managing partner, and Joe Terranova, senior managing director at Virtus Investment Partners, join ‘Closing Bell’ to discuss the CPI report, jobs data impact on the markets, and more.
We’ve seen 18% year-over-year volume growth driven by e-commerce, says Payoneer CEO John Caplan
ShareShare Article via FacebookShare Article via TwitterShare Article via LinkedInShare Article via Email Closing Bell: Overtime John Caplan, Payoneer CEO, joins ‘Closing Bell Overtime’ to talk consumer spending behavior heading into 2024. 03:17 Fri, Dec 29 20236:13 PM EST
